Intercept Pharma (NASDAQ:ICPT): Q3 GAAP EPS of -$2.59 misses by $0.19.
Revenue of $61.95M (+32.1% Y/Y) misses by $1.58M.
Shares +0.2% PM.
Tuesday, November 5, 2019
Mylan EPS beats by $0.03, misses on revenue
Revenue of $2.96B (+3.5% Y/Y) misses by $50M.
Shares +1.6% PM.
Surgery Partners EPS misses by $0.10, beats on revenue
Surgery Partners (NASDAQ:SGRY): Q3 Non-GAAP EPS of -$0.28 misses by $0.10; GAAP EPS of -$0.51 misses by $0.22.
Revenue of $458.3M (+3.2% Y/Y) beats by $6M.
Shares +1.72% PM.
Blueprint Medicines EPS beats by $0.26, beats on revenue
Blueprint Medicines (NASDAQ:BPMC): Q3 GAAP EPS of -$1.93 beats by $0.26.
Revenue of $9.14M (+730.9% Y/Y) beats by $6.29M.
Viking Therapeutics EPS beats by $0.05
Viking Therapeutics (NASDAQ:VKTX): Q3 GAAP EPS of -$0.08 beats by $0.05.
Cash, equivalents and short-term investments of $288.1M.
Shares -0.15% PM.
Mallinckrodt Q3 Acthar sales down 21%
Mallinckrodt (NYSE:MNK) Q3 results:
Sales: $743.7M (-7.0%).
Key product sales: Acthar gel: $229.8M (-20.8%); Inomax: $136.8M (+2.7%).
Net loss: ($1.1M) (-101.0%); non-GAAP net income: $174.5M (-8.6%); loss/share: ($0.01) (-100.7%); non-GAAP EPS: $2.07 (-8.0%).
2019 guidance: EPS: $8.50 – 8.70 from $8.40 – 8.70.
Shares down 2% premarket on light volume.
Henry Schein EPS beats by $0.04, misses on revenue
Henry Schein (NASDAQ:HSIC): Q3 Non-GAAP EPS of $0.90 beats by $0.04; GAAP EPS of $0.91 beats by $0.06.
Revenue of $2.51B (+6.4% Y/Y) misses by $10M.
Subscribe to:
Comments (Atom)